dr. patel on the fda approval of durvalumab in nsclc
Published 6 years ago • 366 plays • Length 0:57Download video MP4
Download video MP3
Similar videos
-
1:36
fda approval of durvalumab for stage iii unresectable nsclc
-
0:58
an expert’s thoughts on the fda approval of durvalumab in locally advanced lung cancers
-
1:49
fda approval of durvalumab for bladder cancer
-
1:58
dr. patel on combination chemotherapy and immunotherapy in lung cancer
-
1:10
dr. patel on primary and adaptive resistance to immunotherapy in nsclc
-
1:10
dr. patel on immunotherapy landscape of stage iv nsclc
-
0:53
dr. siefker-radtke on fda approval of durvalumab in bladder cancer
-
1:35
dr. patel on novel agents for patients with nsclc
-
1:15
dr. spigel on fda approval of pembrolizumab/chemo combo in nsclc
-
1:25
dr. patel on the safety profile of entrectinib in ntrk solid tumors
-
1:08
dr. bazhenova on the pacific trial with durvalumab in nsclc
-
0:53
dr. schwartz on the results of the pacific trial
-
1:42
dr. feldman on the future of durvalumab and tremilimumab in nsclc
-
1:12
dr. patel on benefit of ipilimumab/nivolumab combo in high-grade neuroendocrine carcinoma
-
1:20
dr. simon on durvalumab for patients with lung cancer
-
1:09
dr. patel on benefit of ipilimumab/nivolumab combo in high-grade neuroendocrine carcinoma
-
6:01
fda d.i.s.c.o.: osimertinib for non-small cell lung cancer
-
0:47
dr. feldman on durvalumab for patients with lung cancer
-
1:33
dr. chaft on the rise of immunotherapy in lung cancer